A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

This is a Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma.This study includes a Phase Ia dose-escalation stage and a Phase Ib dose-expansion stage, and it is expected to take approximately 2 years.

Trial Details

NCT ID
NCT07283796
Phase
PHASE1
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • HSK47977
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntarily sign the informed consent form.
  • Age ≥18 years, with no gender restriction.
  • Pathologically confirmed patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →